Neuroprotection in Autism, Schizophrenia and Alzheimer's Disease provides an up-to-date overview on recent clinical studies and the similarities discovered in the most prevalent brain disorders. The book's content will help shed light on basic mechanisms and provide new avenues for early diagnosis toward disease prevention and disease modification. It is written for researchers, clinicians and medical physicians in neuroscience, neurology and psychiatry. Sections discuss the shared pathophysiological mechanisms that underlie autism, schizophrenia/mood disorders and Alzheimer's disease, i.e.…mehr
Neuroprotection in Autism, Schizophrenia and Alzheimer's Disease provides an up-to-date overview on recent clinical studies and the similarities discovered in the most prevalent brain disorders. The book's content will help shed light on basic mechanisms and provide new avenues for early diagnosis toward disease prevention and disease modification. It is written for researchers, clinicians and medical physicians in neuroscience, neurology and psychiatry. Sections discuss the shared pathophysiological mechanisms that underlie autism, schizophrenia/mood disorders and Alzheimer's disease, i.e. neurodevelopmental disorders, neuropsychiatric diseases and neurodegenerative disorders. Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Dr. Illana Gozes is a Professor Emerita at the Sackler Faculty of Medicine and is a faculty of the Sagol School of Neuroscience and Adams Super Center for Brain Studies at Tel Aviv University in Tel Aviv, Israel. She is the incumbent of the Lily and Avraham Gildor Chair for the Investigation of Growth Factors and Heads the Elton Laboratory for Molecular Neuroendocrinology. Prof. Gozes won many awards of excellence (including Bergmann Award, Fogarty-Scholar-in-Residence, Tel Aviv University's Vice President Award-best applied scientist, Olson Prize, Julodan Prize, Teva Prize, Neufeld Award, Hanse-Wissenschaftskolleg (HWK) fellowship, Humboldt Award, Landau Prize for Life Achievements and Champion of Hope - Science International -2016, Global Genes, USA. She is an Ex-President of the Israel Society for Neuroscience, served on the Governing Committee and the Board of Governors of Tel Aviv University, and is currently serving on the Council of the European Society for Neurochemistry,
the Israeli Ministry of Education, Council of Higher Education and is the Israeli coordinator of the International Brain Bee Competition for high school students and the Editor-in-Chief of the Journal of Molecular Neuroscience and serves on many journal editorial boards. Professor is the inventor of numerous patents including CP201(NAP, davunetide), a clinical drug candidate targeted at the rare disease indication, the ADNP syndrome (founded Allon Therapeutics and currently Chief Scientific Officer at Coronis Neurosciences). Professor Gozes discovered ADNP, an essential protein for brain formation implicated in autism, schizophrenia, Alzheimer's disease and cancer. CP201 is a snippet of ADNP, enhancing ADNP's protective activity. Professor Gozes published >320 papers and has an h-index of 73 (Google Scholar).
Inhaltsangabe
Section I. Overview 1. Activity-dependent neuroprotective protein (ADNP)/NAP (CP201): autism, schizophrenia and Alzheimer's disease 2. Clinical convergence of autism, schizophrenia and Alzheimer's disease: The case of social cognition
Section II. Autism 3. A contemporary view on the molecular basis of neurodevelopmental disorders 4. Autism spectrum disorder - A clinical path to early diagnosis, evaluation and intervention 5. Neuro-inflammation and neuroprotection in schizophrenia and autism spectrum disorder
Section III. Neuropsychiatric Disorders 6. Neuroprotective roles of neurotrophic factors in depression 7. Neuroprotective roles of neurotrophic growth factors in mood disorders 8. Heme metabolism, mitochondria and complex I in neuropsychiatric disorders 9. Neuroprotective effects of lithium in neuropsychiatric disorders
Section IV. Alzheimer and Neurodegenerative Diseases 10. Tau-based therapies for Alzheimer´s disease: promising novel neuroprotective approaches 11. Acetylation of tubulin: a feasible protective target from neurodevelopment to neurodegeneration?
Section I. Overview 1. Activity-dependent neuroprotective protein (ADNP)/NAP (CP201): autism, schizophrenia and Alzheimer's disease 2. Clinical convergence of autism, schizophrenia and Alzheimer's disease: The case of social cognition
Section II. Autism 3. A contemporary view on the molecular basis of neurodevelopmental disorders 4. Autism spectrum disorder - A clinical path to early diagnosis, evaluation and intervention 5. Neuro-inflammation and neuroprotection in schizophrenia and autism spectrum disorder
Section III. Neuropsychiatric Disorders 6. Neuroprotective roles of neurotrophic factors in depression 7. Neuroprotective roles of neurotrophic growth factors in mood disorders 8. Heme metabolism, mitochondria and complex I in neuropsychiatric disorders 9. Neuroprotective effects of lithium in neuropsychiatric disorders
Section IV. Alzheimer and Neurodegenerative Diseases 10. Tau-based therapies for Alzheimer´s disease: promising novel neuroprotective approaches 11. Acetylation of tubulin: a feasible protective target from neurodevelopment to neurodegeneration?
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826